The reviewers will use data sources specified in this document and results of stakeholder consultation to describe:
- prevalence of mucopolysaccharidosis type II (MPS II) in Australia
- management of MPS II in comparison to Life Saving Drugs Program (LSDP) guidelines
- clinical and comparative effectiveness and safety of medicines
- relevant patient-based outcomes
- value for money of LSDP treatment for MPS II
- use of the LSDP MPS II medicines
- developing technologies that may impact future access.
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Medicines review protocol
About this resource
Publication date:
Publication type:
Procedure
Audience:
General public
Language:
English
Part of a collection: